These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20218178)

  • 1. [Introduction of acenocoumarol using an algorithm for prescription].
    Notaridis G; Gschwind L; de Moerloose P; Boehlen F
    Rev Med Suisse; 2010 Feb; 6(235):292, 294-7. PubMed ID: 20218178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements.
    van Geest-Daalderop JH; Péquériaux NC; van den Besselaar AM
    Thromb Haemost; 2009 Sep; 102(3):588-92. PubMed ID: 19718481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial.
    Ageno W; Crowther M; Steidl L; Ultori C; Mera V; Dentali F; Squizzato A; Marchesi C; Venco A
    Thromb Haemost; 2002 Jul; 88(1):48-51. PubMed ID: 12152676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
    Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F
    Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of oral anticoagulant therapy in orthopedic and surgical patients: an algorithm compared with routine dosing.
    van den Bemt PM; Beinema M; van Roon EN; Sijtsma J; Baars WA; Mencke HJ; Brouwers JR
    Eur J Clin Pharmacol; 2002 Jun; 58(3):203-208. PubMed ID: 12162272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-care testing and INR within-subject variation in patients receiving a constant dose of vitamin K antagonist.
    van den Besselaar AM; Biedermann JS; Kruip MJ
    Thromb Haemost; 2015 Nov; 114(6):1260-7. PubMed ID: 26202616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
    Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
    Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
    Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
    J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?].
    Lengyel M;
    Orv Hetil; 2004 Dec; 145(52):2619-21. PubMed ID: 15724697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral anticoagulant initiation: rationale for the use of warfarin dosing nomograms.
    Crowther MA
    Semin Vasc Med; 2003 Aug; 3(3):255-60. PubMed ID: 15199458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A retrospective survey on practice of oral anticoagulant therapy in patients with cardiovascular diseases].
    Katona A; Márk L
    Orv Hetil; 2004 Aug; 145(32):1643-7. PubMed ID: 15384862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Normalized Ratio (INR) increase in patients taking oral anticoagulant therapy (OAT) and using sildenafil (Viagra).
    Fernández MA; Romá E
    Haematologica; 2003 Dec; 88(12):ELT34. PubMed ID: 14688013
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral anticoagulation therapy in children.
    Bonduel MM
    Thromb Res; 2006; 118(1):85-94. PubMed ID: 16709477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients who take uneven doses of acenocoumarol exhibit significant fluctuating levels of anticoagulation.
    Marco F; Gutiérrez JI; Orkolaga K; Márquez JA; Ojínaga MJ; de Zárate IO; de Heredia JM
    Blood Coagul Fibrinolysis; 2006 Sep; 17(6):509-12. PubMed ID: 16905959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monitoring of anticoagulant treatment in patients with cancer].
    Mahé I; Bosquet A; Medjkane A; Bal dit Sollier C; Drouet L
    Pathol Biol (Paris); 2008 Jun; 56(4):239-44. PubMed ID: 18407438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin-acenocoumarol interaction.
    Mondillo S; Ballo P; Galderisi M
    Clin Ther; 2005 Jun; 27(6):782-4. PubMed ID: 16117985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.